Vaccines and vaccination strategies against human cutaneous leishmaniasis

Human Vaccines

Volumn 5, Issue 5, 2009, Pages 291-301

  Okwor, Ifeoma ^a   Uzonna, Jude ^a  

^a UNIVERSITY OF MANITOBA   (Canada)

Author keywords

Immune response; Immunomodulators; Leishmania; Leishmanization; Vaccine; Virulent

Indexed keywords

ADJUVANT; BCG VACCINE; CPG OLIGODEOXYNUCLEOTIDE; DENDRITIC CELL VACCINE; DNA VACCINE; GAMMA INTERFERON; GLYCOPROTEIN; GLYCOPROTEIN GP 63; IMIQUIMOD; INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 10; INTERLEUKIN 12; INTERLEUKIN 18; LEISHMANIA HOMOLOG FOR RECEPTOR FOR ACTIVATED C KINASE; LEISHMANIA VACCINE; LIVE VACCINE; LYMPHOTOXIN BETA; MEGLUMINE ANTIMONATE; PLACEBO; RECEPTOR FOR ACTIVATED C KINASE 1; RECOMBINANT INTERLEUKIN 12; SUBUNIT VACCINE; TOLL LIKE RECEPTOR AGONIST; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2; UNCLASSIFIED DRUG;

ADAPTIVE IMMUNITY; CD4+ CD25+ T LYMPHOCYTE; CELL ACTIVATION; CLINICAL TRIAL; DENDRITIC CELL; DOSE RESPONSE; FLOW CYTOMETRY; HUMAN; IMMUNE RESPONSE; IMMUNOLOGY; IMMUNOTHERAPY; LEISHMANIASIS; LOW DRUG DOSE; NONHUMAN; REGULATORY T LYMPHOCYTE; REVIEW; SKIN INFECTION; SKIN LEISHMANIASIS; VACCINATION; VISCERAL LEISHMANIASIS;

ANIMALS; HUMANS; LEISHMANIA; LEISHMANIASIS VACCINES; LEISHMANIASIS, CUTANEOUS; MICE; PRIMATES; VACCINATION;

EID: 70349548782     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.5.5.7607     Document Type: Review

References (159)

1. Desjeux P. Leishmaniasis: Public health aspects and control. Clin Dermatol 1996; 14:417-23.
2. WHO Fact sheet 2000.
3. Ashford RW, Kohestany KA, Karimzad MA. Cutaneous leishmaniasis in Kabul: Observations on a 'prolonged epidemic'. Ann Trop Med Parasitol 1992; 86:361-71.
4. Reithinger R, Brooker S, Kolaczinski JH. Visceral leishmaniasis in eastern Africa - current status. Trans R Soc Trop Med Hyg 2007; 101:1169-70.
5. Stanley AC, Engwerda CR. Balancing immunity and pathology in visceral leishmaniasis. Immunol Cell Biol 2007; 85:138-47.
6. Lessa MM, Lessa HA, Castro TW, Oliveira A, Scherifer A, Machado P, et al. Mucosal leishmaniasis: Epidemiological and clinical aspects. Rev Bras Otorrinolaringol (Engl Ed) 2007; 73:843-7.
7. Amato VS, Tuon FF, Bacha HA, Neto VA, Nicodemo AC. Mucosal leishmaniasis: Current scenario and prospects for treatment. Acta Trop 2008; 105:1-9.
8. Handman E. Leishmaniasis: Current status of vaccine development. Clin Microbiol Rev 2001; 14:229-43.
9. Khamesipour A, Dowlati Y, Asilian A, Hashemi-Fesharki R, Javadi A, Noazin S, et al. Use of an old method for evaluation of candidate vaccines against leishmaniasis. Vaccine 2005; 23:3642-8.
10. Kedzierski L, Zhu Y, Handman E. Leishmania vaccines: Progress and problems. Parasitology 2006; 133:87-112.
11. Assreuy J, Cunha FQ, Epperlein M, Noronha-Dutra A, O'Donnell CA, Liew FY, et al. Production of nitric oxide and superoxide by activated macrophages and killing of Leishmania major. Eur J Immunol 1994; 24:672-6.
12. Moser M, Murphy KM. Dendritic cell regulation of TH1-TH2 development. Nat Immunol 2000; 1:199-205.
13. Moll H. Dendritic cells and host resistance to infection. Cell Microbiol 2003; 5:493-500.
14. Afonso LC, Scharton TM, Vieira LQ, Wysocka M, Trinchieri G, Scott P. The adjuvant effect of interleukin-12 in a vaccine against Leishmania major. Science 1994; 263:235-7.
15. Park AY, Hondowicz BD, Scott P. IL-12 is required to maintain a Th1 response during Leishmania major infection. J Immunol 2000; 165:896-902.
16. Park AY, Hondowicz B, Kopf M, Scott P. The role of IL-12 in maintaining resistance to Leishmania major. J Immunol 2002; 168:5771-7.
17. + T cells resulting in a state of unresponsiveness to IL-12. J Immunol 1998; 161:6156-63.
18. + Th1 cells and early events instructing Th2 cell development and susceptibility to Leishmania major in BALB/c mice. Adv Exp Med Biol 1998; 452:53-60.
19. Louis J, Himmelrich H, Parra-Lopez C, Tacchini-Cottier F, Launois P. Regulation of protective immunity against Leishmania major in mice. Curr Opin Immunol 1998; 10:459-64.
20. Heinzel FP, Rerko RM, Ahmed F, Pearlman E. Endogenous IL-12 is required for control of Th2 cytokine responses capable of exacerbating leishmaniasis in normally resistant mice. J Immunol 1995; 155:730-9.
21. + subsets during murine Leishmania major infection. Res Immunol 1991; 142:28-32.
22. Reiner SL, Locksley RM. The regulation of immunity to Leishmania major. Annu Rev Immunol 1995; 13:151-77.
23. + T-cell subsets in the regulation of parasite immunity and disease. Immunol Rev 1989; 112:161-82.
24. Scott P. The role of TH1 and TH2 cells in experimental cutaneous leishmaniasis. Exp Parasitol 1989; 68:369-72.
25. Scharton-Kersten T, Afonso LC, Wysocka M, Trinchieri G, Scott P. IL-12 is required for natural killer cell activation and subsequent T helper 1 cell development in experimental leishmaniasis. J Immunol 1995; 154:5320-30.
26. Afonso LC, Scott P. Immune responses associated with susceptibility of C57BL/10 mice to Leishmania amazonensis. Infect Immun 1993; 61:2952-9.
27. Himmelrich H, Launois P, Maillard I, Biedermann T, Tacchini-Cottier F, Locksley RM, et al. In BALB/c mice, IL-4 production during the initial phase of infection with Leishmania major is necessary and sufficient to instruct Th2 cell development resulting in progressive disease. J Immunol 2000; 164:4819-25.
28. Mougneau E, Altare F, Wakil AE, Zheng S, Coppola T, Wang ZE, et al. Expression cloning of a protective leishmania antigen. Science 1995; 268:563-6.
29. Matthews DJ, Emson CL, McKenzie GJ, Jolin HE, Blackwell JM, McKenzie AN. IL-13 is a susceptibility factor for Leishmania major infection. J Immunol 2000; 164:1458-62.
30. Sosa MR, Rosas LE, McKenzie AN, Satoskar AR. IL-13 gene-deficient mice are susceptible to cutaneous L. mexicana infection. Eur J Immunol 2001; 31:3255-60.
31. Alexander J, Brombacher F, McGachy HA, McKenzie AN, Walker W, Carter KC. An essential role for IL-13 in maintaining a non-healing response following Leishmania mexicana infection. Eur J Immunol 2002; 32:2923-33.
32. Kane MM, Mosser DM. The role of IL-10 in promoting disease progression in leishmaniasis. J Immunol 2001; 166:1141-7.
33. Groux H, Cottrez F, Rouleau M, Mauze S, Antonenko S, Hurst S, et al. A transgenic model to analyze the immunoregulatory role of IL-10 secreted by antigen-presenting cells. J Immunol 1999; 162:1723-9.
34. Chatelain R, Mauze S, Coffman RL. Experimental Leishmania major infection in mice: Role of IL-10. Parasite Immunol 1999; 21:211-8.
35. Mosmann TR, Moore KW. The role of IL-10 in crossregulation of TH1 and TH2 responses. Immunol Today 1991; 12:49-53.
36. Fiorentino DF, Zlotnik A, Vieira P, Mosmann TR, Howard M, Moore KW, et al. IL-10 acts on the antigen-presenting cell to inhibit cytokine production by Th1 cells. J Immunol 1991; 146:3444-51.
37. Von Stebut E. Immunology of cutaneous leishmaniasis: The role of mast cells, phagocytes and dendritic cells for protective immunity. Eur J Dermatol 2007; 17:115-22.
38. Anderson CF, Oukka M, Kuchroo VJ, Sacks D. CD4(+)CD25(-)Foxp3(-) Th1 cells are the source of IL-10-mediated immune suppression in chronic cutaneous leishmaniasis. J Exp Med 2007; 204:285-97.
39. + regulatory T cells control Leishmania major persistence and immunity. Nature 2002; 420:502-7.
40. Belkaid Y. The role of CD4(+)CD25(+) regulatory T cells in leishmania infection. Expert Opin Biol Ther 2003; 3:875-85.
41. Liew FY, Li Y, Millott S. Tumor necrosis factor-alpha synergizes with IFNγ in mediating killing of Leishmania major through the induction of nitric oxide. J Immunol 1990; 145:4306-10.
42. Liew FY, Parkinson C, Millott S, Severn A, Carrier M. Tumour necrosis factor (TNFalpha) in leishmaniasis I. TNFα mediates host protection against cutaneous leishmaniasis. Immunology 1990; 69:570-3.
43. Nashleanas M, Scott P. Activated T cells induce macrophages to produce NO and control Leishmania major in the absence of tumor necrosis factor receptor p55. Infect Immun 2000; 68:1428-34.
44. Xu G, Liu D, Fan Y, Yang X, Korner H, Fu YX, et al. Lymphotoxin alphabeta2 (membrane lymphotoxin) is critically important for resistance to Leishmania major infection in mice. J Immunol 2007; 179:5358-66.
45. + Th1 cell response, and resistance to Leishmania major. J Immunol 2007; 179:6901-9.
46. Tripathi P, Singh V, Naik S. Immune response to leishmania: Paradox rather than paradigm. FEMS Immunol Med Microbiol 2007; 51:229-42.
47. Ajdary S, Alimohammadian MH, Eslami MB, Kemp K, Kharazmi A. Comparison of the immune profile of nonhealing cutaneous leishmaniasis patients with those with active lesions and those who have recovered from infection. Infect Immun 2000; 68:1760-4.
48. Bottrel RL, Dutra WO, Martins FA, Gontijo B, Carvalho E, Barral-Netto M, et al. Flow cytometric determination of cellular sources and frequencies of key cytokine-producing lymphocytes directed against recombinant LACK and soluble leishmania antigen in human cutaneous leishmaniasis. Infect Immun 2001; 69:3232-9.
49. + T cells without affecting cellular immune responses. Microbiol Immunol 2007; 51:1003-11.
50. Ribeiro-de-Jesus A, Almeida RP, Lessa H, Bacellar O, Carvalho EM. Cytokine profile and pathology in human leishmaniasis. Braz J Med Biol Res 1998; 31:143-8.
51. Follador I, Araujo C, Bacellar O, Araujo CB, Carvalho LP, Almeida RP, et al. Epidemiologic and immunologic findings for the subclinical form of Leishmania braziliensis infection. Clin Infect Dis 2002; 34:54-8.
52. Greenblatt CL. Cutaneous leishmaniasis: The prospects for a killed vaccine. Parasitol Today 1988; 4:53-4.
53. Greenblatt CL. The present and future of vaccination for cutaneous leishmaniasis. Prog Clin Biol Res 1980; 47:259-85.
54. Tabbara KS, Peters NC, Afrin F, Mendez S, Bertholet S, Belkaid Y, et al. Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection. Infect Immun 2005; 73:4714-22.
55. Uzonna JE, Wei G, Yurkowski D, Bretscher P. Immune elimination of Leishmania major in mice: Implications for immune memory, vaccination and reactivation disease. J Immunol 2001; 167:6967-74.
56. Aebischer T, Moody SF, Handman E. Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: A possible hazard for the host. Infect Immun 1993; 61:220-6.
57. Muyombwe A, Olivier M, Harvie P, Bergeron MG, Ouellette M, Papadopoulou B. Protection against Leishmania major challenge infection in mice vaccinated with live recombinant parasites expressing a cytotoxic gene. J Infect Dis 1998; 177:188-95.
58. Muyombwe A, Olivier M, Ouellette M, Papadopoulou B. Selective killing of leishmania amastigotes expressing a thymidine kinase suicide gene. Exp Parasitol 1997; 85:35-42.
59. Davoudi N, Tate CA, Warburton C, Murray A, Mahboudi F, McMaster WR. Development of a recombinant Leishmania major strain sensitive to ganciclovir and 5-fluorocytosine for use as a live vaccine challenge in clinical trials. Vaccine 2005; 23:1170-7.
60. Desjeux P, Alvar J. Leishmania/HIV co-infections: Epidemiology in Europe. Ann Trop Med Parasitol 2003; 97:3-15.
61. Marzochi KB, Marzochi MA, Silva AF, Grativol N, Duarte R, Confort EM, et al. Phase 1 study of an inactivated vaccine against american tegumentary leishmaniasis in normal volunteers in Brazil. Mem Inst Oswaldo Cruz 1998; 93:205-12.
62. Mayrink W, da Costa CA, Magalhaes PA, Melo MN, Dias M, Lima AO, Michalick MS, Williams P. A field trial of a vaccine against American dermal leishmaniasis. Trans R Soc Trop Med Hyg 1979; 73:385-7.
63. Mayrink W, Williams P, da Costa CA, Magalhaes PA, Melo MN, Dias M, et al. An experimental vaccine against American dermal leishmaniasis: Experience in the state of Espirito Santo, Brazil. Ann Trop Med Parasitol 1985; 79:259-69.
64. Botelho AC, Tafuri WL, Genaro O, Mayrink W. Histopathology of human American cutaneous leishmaniasis before and after treatment. Rev Soc Bras Med Trop 1998; 31:11-8.
65. Armijos RX, Weigel MM, Calvopina M, Hidalgo A, Cevallos W, Correa J. Safety, immunogenecity, and efficacy of an autoclaved Leishmania amazonensis vaccine plus BCG adjuvant against new world cutaneous leishmaniasis. Vaccine 2004; 22:1320-6.
66. Velez ID, del Pilar Agudelo S, Arbelaez MP, Gilchrist K, Robledo SM, Puerta JA, et al. Safety and immunogenicity of a killed leishmania (L.) amazonensis vaccine against cutaneous leishmaniasis in Colombia: A randomized controlled trial. Trans R Soc Trop Med Hyg 2000; 94:698-703.
67. Sjolander A, Baldwin TM, Curtis JM, Bengtsson KL, Handman E. Vaccination with recombinant parasite surface antigen 2 from Leishmania major induces a Th1 type of immune response but does not protect against infection. Vaccine 1998; 16:2077-84.
68. Gicheru MM, Olobo JO, Anjili CO, Orago AS, Modabber F, Scott P. Vervet monkeys vaccinated with killed Leishmania major parasites and interleukin-12 develop a type 1 immune response but are not protected against challenge infection. Infect Immun 2001; 69:245-51.
69. Sharifi I, FeKri AR, Aflatonian MR, Khamesipour A, Nadim A, Mousavi MR, et al. Randomised vaccine trial of single dose of killed Leishmania major plus BCG against anthroponotic cutaneous leishmaniasis in Bam, Iran. Lancet 1998; 351:1540-3.
70. Momeni AZ, Jalayer T, Emamjomeh M, Khamesipour A, Zicker F, Ghassemi RL, et al. A randomised, double-blind, controlled trial of a killed L. major vaccine plus BCG against zoonotic cutaneous leishmaniasis in Iran. Vaccine 1999; 17:466-72.
71. Khalil EA, El Hassan AM, Zijlstra EE, Mukhtar MM, Ghalib HW, Musa B, et al. Autoclaved Leishmania major vaccine for prevention of visceral leishmaniasis: A randomised, double-blind, BCG-controlled trial in Sudan. Lancet 2000; 356:1565-9.
72. Vilela Mde C, Gomes DC, Marques-da-Silva Ede A, Serafim TD, Afonso LC, Rezende SA. Successful vaccination against leishmania chagasi infection in BALB/c mice with freeze-thawed leishmania antigen and corynebacterium parvum. Acta Trop 2007; 104:133-9.
73. Titus RG, Gueiros-Filho FJ, de Freitas LA, Beverley SM. Development of a safe live leishmania vaccine line by gene replacement. Proc Natl Acad Sci USA 1995; 92:10267-71.
74. Brodskyn C, Beverley SM, Titus RG. Virulent or avirulent (dhfr-ts-) Leishmania major elicit predominantly a type-1 cytokine response by human cells in vitro. Clin Exp Immunol 2000; 119:299-304.
75. Amaral VF, Teva A, Oliveira-Neto MP, Silva AJ, Pereira MS, Cupolillo E, et al. Study of the safety, immunogenicity and efficacy of attenuated and killed leishmania (leishmania) major vaccines in a rhesus monkey (macaca mulatta) model of the human disease. Mem Inst Oswaldo Cruz 2002; 97:1041-8.
76. Alexander J, Coombs GH, Mottram JC. Leishmania mexicana cysteine proteinase-deficient mutants have attenuated virulence for mice and potentiate a Th1 response. J Immunol 1998; 161:6794-801.
77. Huang C, Turco SJ. Defective galactofuranose addition in lipophosphoglycan biosynthesis in a mutant of Leishmania donovani. J Biol Chem 1993; 268:24060-6.
78. Ryan KA, Garraway LA, Descoteaux A, Turco SJ, Beverley SM. Isolation of virulence genes directing surface glycosyl-phosphatidylinositol synthesis by functional complementation of leishmania. Proc Natl Acad Sci USA 1993; 90:8609-13.
79. Spath GF, Lye LF, Segawa H, Sacks DL, Turco SJ, Beverley SM. Persistence without pathology in phosphoglycan-deficient Leishmania major. Science 2003; 301:1241-3.
80. Uzonna JE, Spath GF, Beverley SM, Scott P. Vaccination with phosphoglycan-deficient Leishmania major protects highly susceptible mice from virulent challenge without inducing a strong Th1 response. J Immunol 2004; 172:3793-7.
81. Spath GF, Lye LF, Segawa H, Turco SJ, Beverley SM. Identification of a compensatory mutant (lpg2-REV) of Leishmania major able to survive as amastigotes within macrophages without LPG2-dependent glycoconjugates and its significance to virulence and immunization strategies. Infect Immun 2004; 72:3622-7.
82. Kebaier C, Uzonna JE, Beverley SM, Scott P. Immunization with persistent attenuated delta lpg2 Leishmania major parasites requires adjuvant to provide protective immunity in C57BL/6 mice. Infect Immun 2006; 74:777-80.
83. Breton M, Tremblay MJ, Ouellette M, Papadopoulou B. Live nonpathogenic parasitic vector as a candidate vaccine against visceral leishmaniasis. Infect Immun 2005; 73:6372-82.
84. Silvestre R, Cordeiro-Da-Silva A, Santarem N, Vergnes B, Sereno D, Ouaissi A. SIR2-deficient leishmania infantum induces a defined IFNγ/IL-10 pattern that correlates with protection. J Immunol 2007; 179:3161-70.
85. Thiakaki M, Kolli B, Chang KP, Soteriadou K. Downregulation of gp63 level in Leishmania amazonensis promastigotes reduces their infectivity in BALB/c mice. Microbes Infect 2006; 8:1455-63.
86. Handman E, Button LL, McMaster RW. Leishmania major: Production of recombinant gp63, its antigenicity and immunogenicity in mice. Exp Parasitol 1990; 70:427-35.
87. Olobo JO, Anjili CO, Gicheru MM, Mbati PA, Kariuki TM, Githure JI, et al. Vaccination of vervet monkeys against cutaneous leishmaniosis using recombinant leishmania 'major surface glycoprotein' (gp63). Vet Parasitol 1995; 60:199-212.
88. Russell DG, Alexander J. Effective immunization against cutaneous leishmaniasis with defined membrane antigens reconstituted into liposomes. J Immunol 1988; 140:1274-9.
89. Rivier D, Bovay P, Shah R, Didisheim S, Mauel J. Vaccination against Leishmania major in a CBA mouse model of infection: Role of adjuvants and mechanism of protection. Parasite Immunol 1999; 21:461-73.
90. Abdelhak S, Louzir H, Timm J, Blel L, Benlasfar Z, Lagranderie M, et al. Recombinant BCG expressing the leishmania surface antigen Gp63 induces protective immunity against Leishmania major infection in BALB/c mice. Microbiology 1995; 141:1585-92.
91. Yang DM, Fairweather N, Button LL, McMaster WR, Kahl LP, Liew FY. Oral salmonella typhimurium (AroA-) vaccine expressing a major leishmanial surface protein (gp63) preferentially induces T helper 1 cells and protective immunity against leishmaniasis. J Immunol 1990; 145:2281-5.
92. Gonzalez CR, Noriega FR, Huerta S, Santiago A, Vega M, Paniagua J, et al. Immunogenicity of a salmonella typhi CVD 908 candidate vaccine strain expressing the major surface protein gp63 of Leishmania mexicana mexicana. Vaccine 1998; 16:1043-52.
93. Kemp M, Theander TG, Handman E, Hey AS, Kurtzhals JA, Hviid L, et al. Activation of human T lymphocytes by leishmania lipophosphoglycan. Scand J Immunol 1991; 33:219-24.
94. Bhowmick S, Ravindran R, Ali N. gp63 in stable cationic liposomes confers sustained vaccine immunity to susceptible BALB/c mice infected with Leishmania donovani. Infect Immun 2008; 76:1003-15.
95. Gomes DC, Pinto EF, de Melo LD, Lima WP, Larraga V, Lopes UG, et al. Intranasal delivery of naked DNA encoding the LACK antigen leads to protective immunity against visceral leishmaniasis in mice. Vaccine 2007; 25:2168-72.
96. Gurunathan S, Sacks DL, Brown DR, Reiner SL, Charest H, Glaichenhaus N, et al. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 1997; 186:1137-47.
97. Gurunathan S, Prussin C, Sacks DL, Seder RA. Vaccine requirements for sustained cellular immunity to an intracellular parasitic infection. Nat Med 1998; 4:1409-15.
98. Gonzalo RM, Rodriguez JR, Rodriguez D, Gonzalez-Aseguinolaza G, Larraga V, Esteban M. Protective immune response against cutaneous leishmaniasis by prime/booster immunization regimens with vaccinia virus recombinants expressing leishmania infantum p36/LACK and IL-12 in combination with purified p36. Microbes Infect 2001; 3:701-11.
99. Gonzalo RM, del Real G, Rodriguez JR, Rodriguez D, Heljasvaara R, Lucas P, et al. A heterologous prime-boost regime using DNA and recombinant vaccinia virus expressing the leishmania infantum p36/LACK antigen protects BALB/c mice from cutaneous leishmaniasis. Vaccine 2002; 20:1226-31.
100. Melby PC, Yang J, Zhao W, Perez LE, Cheng J. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis. Infect Immun 2001; 69:4719-25.
101. Ramos I, Alonso A, Marcen JM, Peris A, Castillo JA, Colmenares M, et al. Heterologous prime-boost vaccination with a non-replicative vaccinia recombinant vector expressing LACK confers protection against canine visceral leishmaniasis with a predominant Th1-specific immune response. Vaccine 2008; 26:333-44.
102. Rafati S, Nakhaee A, Taheri T, Ghashghaii A, Salmanian AH, Jimenez M, et al. Expression of cysteine proteinase type I and II of leishmania infantum and their recognition by sera during canine and human visceral leishmaniasis. Exp Parasitol 2003; 103:143-51.
103. Rafati S, Salmanian AH, Hashemi K, Schaff C, Belli S, Fasel N. Identification of Leishmania major cysteine proteinases as targets of the immune response in humans. Mol Biochem Parasitol 2001; 113:35-43.
104. Zadeh-Vakili A, Taheri T, Taslimi Y, Doustdari F, Salmanian AH, Rafati S. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases type I (CPB) and type II (CPA), partially protects against leishmaniasis. Vaccine 2004; 22:1930-40.
105. Soong L, Duboise SM, Kima P, McMahon-Pratt D. Leishmania pifanoi amastigote antigens protect mice against cutaneous leishmaniasis. Infect Immun 1995; 63:3559-66.
106. + T cells. Infect Immun 2007; 75:4648-54.
107. Coler RN, Skeiky YA, Bernards K, Greeson K, Carter D, Cornellison CD, et al. Immunization with a polyprotein vaccine consisting of the T-cell antigens thiol-specific antioxidant, Leishmania major stress-inducible protein 1, and leishmania elongation initiation factor protects against leishmaniasis. Infect Immun 2002; 70:4215-25.
108. Skeiky YA, Coler RN, Brannon M, Stromberg E, Greeson K, Crane RT, et al. Protective efficacy of a tandemly linked, multi-subunit recombinant leishmanial vaccine (leish-111f) formulated in MPL adjuvant. Vaccine 2002; 20:3292-303.
109. Launois P, Tacchini-Cottier F, Kieny MP. Cutaneous leishmaniasis: Progress towards a vaccine. Expert Rev Vaccines 2008; 7:1277-87.
110. Fernandes AP, Costa MM, Coelho EA, Michalick MS, de Freitas E, Melo MN, et al. Protective immunity against challenge with leishmania (leishmania) chagasi in beagle dogs vaccinated with recombinant A2 protein. Vaccine 2008; 26:5888-95.
111. + T cells play a dominant role in protection against new world leishmaniasis induced by vaccination with the P-4 amastigote antigen. Infect Immun 2005; 73:3823-7.
112. Iborra S, Abanades DR, Parody N, Carrion J, Risueno RM, Pineda MA, et al. The immunodominant T helper 2 (Th2) response elicited in BALB/c mice by the leishmania LiP2a and LiP2b acidic ribosomal proteins cannot be reverted by strong Th1 inducers. Clin Exp Immunol 2007; 150:375-85.
113. Handman E, Symons FM, Baldwin TM, Curtis JM, Scheerlinck JP. Protective vaccination with promastigote surface antigen 2 from Leishmania major is mediated by a TH1 type of immune response. Infect Immun 1995; 63:4261-7.
114. Huygen K. Plasmid DNA vaccination. Microbes Infect 2005; 7:932-8.
115. Gurunathan S, Klinman DM, Seder RA. DNA vaccines: Immunology, application and optimization*. Annu Rev Immunol 2000; 18:927-74.
116. Alarcon JB, Waine GW, McManus DP. DNA vaccines: Technology and application as anti-parasite and anti-microbial agents. Adv Parasitol 1999; 42:343-410.
117. Restifo NP, Ying H, Hwang L, Leitner WW. The promise of nucleic acid vaccines. Gene Ther 2000; 7:89-92.
118. McShane H. Prime-boost immunization strategies for infectious diseases. Curr Opin Mol Ther 2002; 4:23-7.
119. Xu D, Liew FY. Protection against leishmaniasis by injection of DNA encoding a major surface glycoprotein, gp63, of L. major. Immunology 1995; 84:173-6.
120. Ahmed SB, Bahloul C, Robbana C, Askri S, Dellagi K. A comparative evaluation of different DNA vaccine candidates against experimental murine leishmaniasis due to L. major. Vaccine 2004; 22:1631-9.
121. Tapia E, Perez-Jimenez E, Lopez-Fuertes L, Gonzalo R, Gherardi MM, Esteban M. The combination of DNA vectors expressing IL-12 + IL-18 elicits high protective immune response against cutaneous leishmaniasis after priming with DNA-p36/LACK and the cytokines, followed by a booster with a vaccinia virus recombinant expressing p36/LACK. Microbes Infect 2003; 5:73-84.
122. Zavala F, Rodrigues M, Rodriguez D, Rodriguez JR, Nussenzweig RS, Esteban M. A striking property of recombinant poxviruses: Efficient inducers of in vivo expansion of primed CD8(+) T cells. Virology 2001; 280:155-9.
123. Lange UG, Mastroeni P, Blackwell JM, Stober CB. DNA-salmonella enterica serovar typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice. Infect Immun 2004; 72:4924-8.
124. Lopez-Fuertes L, Perez-Jimenez E, Vila-Coro AJ, Sack F, Moreno S, Konig SA, et al. DNA vaccination with linear minimalistic (MIDGE) vectors confers protection against Leishmania major infection in mice. Vaccine 2002; 21:247-57.
125. Rafati S, Zahedifard F, Nazgouee F. Prime-boost vaccination using cysteine proteinases type I and II of leishmania infantum confers protective immunity in murine visceral leishmaniasis. Vaccine 2006; 24:2169-75.
126. Rafati S, Nakhaee A, Taheri T, Taslimi Y, Darabi H, Eravani D, et al. Protective vaccination against experimental canine visceral leishmaniasis using a combination of DNA and protein immunization with cysteine proteinases type I and II of L. infantum. Vaccine 2005; 23:3716-25.
127. Carrion J, Folgueira C, Alonso C. Immunization strategies against visceral leishmaniosis with the nucleosomal histones of leishmania infantum encoded in DNA vaccine or pulsed in dendritic cells. Vaccine 2008; 26:2537-44.
128. Zanin FH, Coelho EA, Tavares CA, Marques-da-Silva EA, Silva Costa MM, Rezende SA, et al. Evaluation of immune responses and protection induced by A2 and nucleoside hydrolase (NH) DNA vaccines against leishmania chagasi and Leishmania amazonensis experimental infections. Microbes Infect 2007; 9:1070-7.
129. Montalvo-Alvarez AM, Folgueira C, Carrion J, Monzote-Fidalgo L, Canavate C, Requena JM. The leishmania HSP20 is antigenic during natural infections, but, as DNA vaccine, it does not protect BALB/c mice against experimental L. amazonensis infection. J Biomed Biotechnol 2008; 2008:695432.
130. Banchereau J, Briere F, Caux C, Davoust J, Lebecque S, Liu YJ, et al. Immunobiology of dendritic cells. Annu Rev Immunol 2000; 18:767-811.
131. Flohe SB, Bauer C, Flohe S, Moll H. Antigen-pulsed epidermal langerhans cells protect susceptible mice from infection with the intracellular parasite Leishmania major. Eur J Immunol 1998; 28:3800-11.
132. Remer KA, Apetrei C, Schwarz T, Linden C, Moll H. Vaccination with plasmacytoid dendritic cells induces protection against infection with Leishmania major in mice. Eur J Immunol 2007; 37:2463-73.
133. von Stebut E, Belkaid Y, Jakob T, Sacks DL, Udey MC. Uptake of Leishmania major amastigotes results in activation and interleukin 12 release from murine skin-derived dendritic cells: Implications for the initiation of anti-leishmania immunity. J Exp Med 1998; 188:1547-52.
134. Ahuja SS, Reddick RL, Sato N, Montalbo E, Kostecki V, Zhao W, et al. Dendritic cell (DC)-based anti-infective strategies: DCs engineered to secrete IL-12 are a potent vaccine in a murine model of an intracellular infection. J Immunol 1999; 163:3890-7.
135. Ramirez-Pineda JR, Frohlich A, Berberich C, Moll H. Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC. J Immunol 2004; 172:6281-9.
136. Berberich C, Ramirez-Pineda JR, Hambrecht C, Alber G, Skeiky YA, Moll H. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens. J Immunol 2003; 170:3171-9.
137. Kronenberg K, Brosch S, Von Stebut E. Vaccinations against cutaneous leishmania infection. G Ital Dermatol Venereol 2008; 143:125-37.
138. Titus RG, Ribeiro JM. Salivary gland lysates from the sand fly lutzomyia longipalpis enhance leishmania infectivity. Science 1988; 239:1306-8.
139. Kamhawi S, Belkaid Y, Modi G, Rowton E, Sacks D. Protection against cutaneous leishmaniasis resulting from bites of uninfected sand flies. Science 2000; 290:1351-4.
140. Morris RV, Shoemaker CB, David JR, Lanzaro GC, Titus RG. Sandfly maxadilan exacerbates infection with Leishmania major and vaccinating against it protects against L. major infection. J Immunol 2001; 167:5226-30.
141. Gomes R, Teixeira C, Teixeira MJ, Oliveira F, Menezes MJ, Silva C, et al. Immunity to a salivary protein of a sand fly vector protects against the fatal outcome of visceral leishmaniasis in a hamster model. Proc Natl Acad Sci USA 2008; 105:7845-50.
142. Bhowmick S, Ali N. Recent developments in leishmaniasis vaccine delivery systems. Expert Opin Drug Deliv 2008; 5:789-803.
143. Misra A, Dube A, Srivastava B, Sharma P, Srivastava JK, Katiyar JC, et al. Successful vaccination against Leishmania donovani infection in indian langur using alum-precipitated autoclaved Leishmania major with BCG. Vaccine 2001; 19:3485-92.
144. Kamil AA, Khalil EA, Musa AM, Modabber F, Mukhtar MM, Ibrahim ME, et al. Alum-precipitated autoclaved Leishmania major plus bacille calmette-guerrin, a candidate vaccine for visceral leishmaniasis: Safety, skin-delayed type hypersensitivity response and dose finding in healthy volunteers. Trans R Soc Trop Med Hyg 2003; 97:365-8.
145. Khalil EA, Musa AM, Modabber F, El-Hassan AM. Safety and immunogenicity of a candidate vaccine for visceral leishmaniasis (alum-precipitated autoclaved Leishmania major + BCG) in children: An extended phase II study. Ann Trop Paediatr 2006; 26:357-61.
146. Constantinescu CS, Hondowicz BD, Elloso MM, Wysocka M, Trinchieri G, Scott P. The role of IL-12 in the maintenance of an established Th1 immune response in experimental leishmaniasis. Eur J Immunol 1998; 28:2227-33.
147. Webb JR, Campos-Neto A, Ovendale PJ, Martin TI, Stromberg EJ, Badaro R, et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect Immun 1998; 66:3279-89.
148. Aebischer T, Wolfram M, Patzer SI, Ilg T, Wiese M, Overath P. Subunit vaccination of mice against new world cutaneous leishmaniasis: Comparison of three proteins expressed in amastigotes and six adjuvants. Infect Immun 2000; 68:1328-36.
149. Campos-Neto A, Porrozzi R, Greeson K, Coler RN, Webb JR, Seiky YA, et al. Protection against cutaneous leishmaniasis induced by recombinant antigens in murine and nonhuman primate models of the human disease. Infect Immun 2001; 69:4103-8.
150. Zimmermann S, Egeter O, Hausmann S, Lipford GB, Rocken M, Wagner H, et al. CpG oligodeoxynucleotides trigger protective and curative Th1 responses in lethal murine leishmaniasis. J Immunol 1998; 160:3627-30.
151. Mendez S, Tabbara K, Belkaid Y, Bertholet S, Verthelyi D, Klinman D, et al. Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous leishmaniasis but maintains its potency and durability. Infect Immun 2003; 71:5121-9.
152. + T cell responses and protection against Leishmania major infection. J Exp Med 2002; 195:1565-73.
153. Iborra S, Parody N, Abanades DR, Bonay P, Prates D, Novais FO, et al. Vaccination with the Leishmania major ribosomal proteins plus CpG oligodeoxynucleotides induces protection against experimental cutaneous leishmaniasis in mice. Microbes Infect 2008; 10:1133-41.
154. Gibson SJ, Imbertson LM, Wagner TL, Testerman TL, Reiter MJ, Miller RL, et al. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res 1995; 15:537-45.
155. Buates S, Matlashewski G. Treatment of experimental leishmaniasis with the immunomodulators imiquimod and S-28463: Efficacy and mode of action. J Infect Dis 1999; 179:1485-94.
156. Arevalo I, Ward B, Miller R, Meng TC, Najar E, Alvarez E, et al. Successful treatment of drug-resistant cutaneous leishmaniasis in humans by use of imiquimod, an immunomodulator. Clin Infect Dis 2001; 33:1847-51.
157. Firooz A, Khamesipour A, Ghoorchi MH, Nassiri-Kashani M, Eskandari SE, Khatami A, et al. Imiquimod in combination with meglumine antimoniate for cutaneous leishmaniasis: A randomized assessor-blind controlled trial. Arch Dermatol 2006; 142:1575-9.
158. Zhang WW, Matlashewski G. Immunization with a toll-like receptor 7 and/ or 8 agonist vaccine adjuvant increases protective immunity against Leishmania major in BALB/c mice. Infect Immun 2008; 76:3777-83.
159. Zaph C, Uzonna J, Beverley SM, Scott P. Central memory T cells mediate long-term immunity to Leishmania major in the absence of persistent parasites. Nat Med 2004; 10:1104-10.